以不断涌现的创新药管线的大额BD交易为显著标志,中国创新药行业正在迎来基于源头创新基础之上的新一轮繁荣盛世。这一轮创新药产业的全面复苏,带来的不仅仅是创新药企业在资本层面的估值修复,还将带来一整条创新药产业链的价值重塑。以上游的CXO行业和下游的互联网分销平台为代表的创新药配套产业链,将有望收获新一轮的增长周期,成为这一轮创新药的盛世中的“隐形赢家”。CXO行业的王者归来作为中国乃至全球CXO行业...
Source Link以不断涌现的创新药管线的大额BD交易为显著标志,中国创新药行业正在迎来基于源头创新基础之上的新一轮繁荣盛世。这一轮创新药产业的全面复苏,带来的不仅仅是创新药企业在资本层面的估值修复,还将带来一整条创新药产业链的价值重塑。以上游的CXO行业和下游的互联网分销平台为代表的创新药配套产业链,将有望收获新一轮的增长周期,成为这一轮创新药的盛世中的“隐形赢家”。CXO行业的王者归来作为中国乃至全球CXO行业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.